Brief: Celyad Oncology Q1 Cash At EUR 20.5 Million

Celyad Oncology SA

06/05/2022 06:19

May 6 (Reuters) - CELYAD ONCOLOGY  CYAD.BR :
    * ANNOUNCED ON THURSDAY Q1 RESULTS 
    * END-MARCH CASH AND CASH EQUIVALENTS OF EUR 20.5 MLN
    * END MARCH NET CASH BURN EUR 9.5 MLN
    * OUTLOOK: CONFIRMS GUIDANCE THAT EXISTING CASH AND CASH
EQUIVALENTS, WITH REMAINING ACCESS TO EQUITY PURCHASE AGREEMENT
WITH LINCOLN PARK CAPITAL FUND SHOULD BE SUFFICIENT TO FUND
OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS UNTIL
MID-2023
    * OUTLOOK: CONTINUE TO INVESTIGATE THE RECENT DEVELOPMENTS
IN THE
CYAD-101 PHASE 1B TRIAL
    * OUTLOOK: PROGRESS WITH SHRNA-BASED ALLOGENEIC PROGRAMS,
INCLUDING CYAD-211, FOR WHICH WE ANTICIPATE ANNOUNCING
ADDITIONAL DATA in H2 2022

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nBw6Cf5PCa
 Further company coverage:  CYAD.BR  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))